Cagrilintide
ResearchA long-acting amylin analog researched for weight loss, particularly in combination with semaglutide (the CagriSema combination).
Weight ManagementMetabolic Health
Half Life
~7-8 days
Time to Results
4-12 weeks
Administration
SubQ injection
🐾 Griffin's Research Scorecard
Research Strength
Human Data
Animal Data
Long-Term Data
Beginner Friendly
Storage Difficulty
Injection FrequencyOnce weekly
Cost$$$
🐾 Griffin Says...
The CagriSema combination (cagrilintide plus semaglutide) is showing some of the most remarkable weight loss data in clinical trials, potentially outperforming tirzepatide. The amylin receptor angle adds a different pathway to the GLP-1 action.
Benefits
- Weight reduction
- Appetite suppression
- Complementary to GLP-1 agonists
- Blood sugar regulation
- Satiety improvement
Best For
- Advanced weight management research
- Combination therapy research
Body Systems
MetabolicEndocrineNervous System
Mechanisms of Action
- Amylin receptor agonist
- Slows gastric emptying
- Reduces appetite via CNS
- Synergistic with GLP-1 receptor agonists
Side Effects
| Effect | Frequency | Severity |
|---|---|---|
| Nausea | Common | Mild |
| Vomiting | Uncommon | Mild |
| Injection site reactions | Common | Mild |
Contraindications
Not yet approved, limited long-term data
Peptides discussed here are for research purposes only. Nothing on this page is medical advice. Always consult a qualified professional before making health decisions.
Ready to calculate your dose? Use Griffin's Peptide Calculator 🐾
Open Calculator